Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinical cou
2020
https://researcherprofiles.org/profile/113322894
32475834
Konig MF, Gianfrancesco M, Yazdany J, Robinson PC
